OTC · BIOE
Bio Essence Corporation
$0.44+$0.02 (+4.76%)
Bio Essence Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.89% below the high.
Loading market information…
OTC · RAFA · USD
Stock price
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rafarma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.44+$0.02 (+4.76%)
Bio Essence Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.89% below the high.
$0.00+$0.00 (+16.67%)
Integrated Cannabis Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.83% below the high.
CA$0.02-CA$0.01 (-25.0%)
Revive Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 81.25% below the high.
$0.00$0.00 (0.0%)
Ubiquitech Software Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00+$0.00 (+50.0%)
LiveWire Ergogenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.57% below the high.
CA$0.01CA$0.00 (0.0%)
Pharmadrug Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Resilient Healthcare Corp’s quoted price sits in the lower half of its reported 52-week range, 92.98% below the high.
$0.00$0.00 (0.0%)
StateHouse Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.33% below the high.
